+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028

  • ID: 4773769
  • Report
  • October 2021
  • Region: Global
  • 219 Pages
  • Triton Market Research

FEATURED COMPANIES

  • Baxter International Inc
  • Cognoptix Inc
  • Eli Lilly & Company
  • GE Healthcare
  • Lupin Limited
  • Merck & Co Inc

MARKET OUTLOOK


The global Alzheimer’s disease therapeutics and diagnostics market is expected to develop with a CAGR of 5.56% during the forecast years from 2021 to 2028.

The growing dementia prevalence in the elderly populace and the high prevalence of Alzheimer’s among people in developed countries are key factors driving the growth of this market. In addition, the launch of new drugs and the prevailing clinical trials are also resulting in robust growth of the Alzheimer’s disease therapeutics and diagnostics market.

On the flip side, stringent regulations concerning drug development and clinical trials, as well as the failure of the late-stage drugs to bring about significant improvement in symptoms, are hampering the growth of this industry. On the bright side, emerging novel diagnostic technologies for Alzheimer’s disease treatment are creating new avenues for the development of this market.

REGIONAL OUTLOOK


Europe, the Asia-Pacific, Latin America, the Middle East and Africa, and North America together shape the global market for Alzheimer’s therapeutics and diagnostics.

Presently, North America holds the largest share of the global market, and is expected to maintain its dominance by the end of the forecast period. Developed countries such as the United States and Canada are a part of this region. The growth of the market here can be attributed to the rising geriatric population and the growing burden of Alzheimer’s disease. As per statistics, 1 in 9 people aged 65 years and above in the US is said to have Alzheimer’s dementia. Presently, several research studies are going on in the country on developing novel therapeutics and diagnostics for the disease, along with launching new products. All these factors are encouraging the growth of the market in North America.

COMPETITIVE OUTLOOK


Some of the major players engaged in the Alzheimer’s disease therapeutics and diagnostics market include F Hoffmann La Roche, Eisai Co Ltd, Novartis AG, Baxter International Inc, GE Healthcare, Luye Pharma Group, Siemens Healthineers AG, Lupin Limited, Amarantus Bioscience Holdings Inc, Merck & Co Inc, Johnson & Johnson, Teva Pharmaceutical Industries Limited, Eli Lilly & Company, Cognoptix Inc, PeopleBio Co, Zydus Cadila, Allergan Plc acquired by Abbvie, Sun Pharmaceuticals Industries Ltd, Biogen Inc, and Pfizer Inc.

Allergan Plc specializes in pharmaceuticals, with a primary focus on the development, manufacture, marketing, and distribution of specialty branded, biosimilar, and OTC products. The company has strengthened its product portfolio with various product launches and approvals. Its product NAMZARIC helps fight the symptoms of moderate to severe Alzheimer’s disease. Founded in 2013, the company has more than 1,200 employees across the globe; it operates in several countries, such as the US, China, Canada, India, and other high growth markets in Europe, the Middle East, Southeast Asia, and Latin America. In May 2020, the company was acquired by AbbVie.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Baxter International Inc
  • Cognoptix Inc
  • Eli Lilly & Company
  • GE Healthcare
  • Lupin Limited
  • Merck & Co Inc

1. Global Alzheimer's Disease Therapeutics and Diagnostics Market - Summary
2. Industry Outlook
2.1. Key Insights
2.2. Impact of Covid-19 on the Alzheimer's Disease Therapeutics and Diagnostics Market
2.3. Porter's Five Forces Model
2.3.1. Threat of New Entrants
2.3.2. Threat of Substitute Products
2.3.3. Bargaining Power of Buyers
2.3.4. Bargaining Power of Suppliers
2.3.5. Competitive Rivalry
2.4. Key Buying Impact Analysis
2.5. Industry Components
2.6. Different Phases of Alzheimer's Disease
2.7. Market Attractiveness Index
2.8. Vendor Scorecard
2.9. Key Strategic Developments
2.9.1. Contracts & Partnerships
2.9.2. Divestitures Business Expansions & Divestitures
2.9.3. Acquisitions & Mergers
2.9.4. New Product Launches
2.10. Market Drivers
2.10.1. Growing Dementia Among the Elderly
2.10.2. High Prevalence of Alzheimer's Disease in Developed Countries
2.10.3. Launch of New Drugs and the Prevailing Clinical Trials Resulting in Robust Market Growth
2.11. Market Challenges
2.11.1. Stringent Regulations Associated With Drug Development and Clinical Trials
2.11.2. Failure of the Late-Stage Drugs to Induce Significant Improvement in Symptoms
2.12. Market Opportunities
2.12.1. Emerging Novel Diagnostic Technologies for Alzheimer's Disease Treatment
3. Global Alzheimer's Disease Therapeutics and Diagnostics Market - by Therapeutics and Diagnostics
3.1. Therapeutics
3.1.1. Therapeutics by Drugs
3.1.1.1. Marketed Drugs
3.1.1.2. Pipeline Drugs
3.1.2. Therapeutics by Disease Stage
3.1.2.1. Late Stage: Severe Ad
3.1.2.2. Early/Middle Stage: Mild to Moderate Ad
3.1.2.3. Prodromal Stage
3.1.3. Therapeutics by Generic and Branded
3.1.3.1. Branded
3.1.3.2. Generic
3.2. Diagnostics
3.2.1. Lumbar Puncture Test
3.2.2. Positron Emission Tomography
3.2.3. Electroencephalography
3.2.4. Magnetic Resonance Imaging
3.2.5. Computed Tomography
3.2.6. Blood Test
3.2.7. Other Diagnostics
4. Global Alzheimer's Disease Therapeutics and Diagnostics Market - Regional Outlook
4.1. North America
4.1.1. Market by Therapeutics and Diagnostics
4.1.1.1. Therapeutics Market by Drugs
4.1.1.2. Therapeutics Market by Disease Stage
4.1.1.3. Therapeutics Market by Generic and Branded
4.1.1.4. Diagnostics Market by Type
4.1.2. Country Analysis
4.1.2.1. The United States
4.1.2.2. Canada
4.2. Europe
4.2.1. Market by Therapeutics and Diagnostics
4.2.1.1. Therapeutics Market by Drugs
4.2.1.2. Therapeutics Market by Disease Stage
4.2.1.3. Therapeutics Market by Generic and Branded
4.2.1.4. Diagnostics Market by Type
4.2.2. Country Analysis
4.2.2.1. United Kingdom
4.2.2.2. France
4.2.2.3. Germany
4.2.2.4. Italy
4.2.2.5. Russia
4.2.2.6. Spain
4.2.2.7. Rest of Europe
4.3. Asia-Pacific
4.3.1. Market by Therapeutics and Diagnostics
4.3.1.1. Therapeutics Market by Drugs
4.3.1.2. Therapeutics Market by Disease Stage
4.3.1.3. Therapeutics Market by Generic and Branded
4.3.1.4. Diagnostics Market by Type
4.3.2. Country Analysis
4.3.2.1. China
4.3.2.2. India
4.3.2.3. Japan
4.3.2.4. Australia & New Zealand
4.3.2.5. South Korea
4.3.2.6. Asean Countries
4.3.2.7. Rest of Asia-Pacific
4.4. Latin America
4.4.1. Market by Therapeutics and Diagnostics
4.4.1.1. Therapeutics Market by Drugs
4.4.1.2. Therapeutics Market by Disease Stage
4.4.1.3. Therapeutics Market by Generic and Branded
4.4.1.4. Diagnostics Market by Type
4.4.2. Country Analysis
4.4.2.1. Brazil
4.4.2.2. Mexico
4.4.2.3. Rest of Latin America
4.5. Middle East and Africa
4.5.1. Market by Therapeutics and Diagnostics
4.5.1.1. Therapeutics Market by Drugs
4.5.1.2. Therapeutics Market by Disease Stage
4.5.1.3. Therapeutics Market by Generic and Branded
4.5.1.4. Diagnostics Market by Type
4.5.2. Country Analysis
4.5.2.1. Saudi Arabia
4.5.2.2. United Arab Emirates
4.5.2.3. Turkey
4.5.2.4. South Africa
4.5.2.5. Rest of Middle East & Africa
5. Company Profiles
5.1. Allergan plc Acquired by Abbvie
5.2. Amarantus Bioscience Holdings Inc
5.3. Baxter International Inc
5.4. Biogen Inc
5.5. Cognoptix Inc
5.6. Eisai Co Ltd
5.7. Eli Lilly & Company
5.8. F Hoffmann La Roche
5.9. GE Healthcare
5.10. Johnson & Johnson
5.11. Lupin Limited
5.12. Luye Pharma Group
5.13. Merck & Co Inc
5.14. Novartis AG
5.15. Peoplebio Co
5.16. Pfizer Inc
5.17. Siemens Healthineers AG
5.18. Sun Pharmaceuticals Industries Ltd
5.19. Teva Pharmaceutical Industries Limited
5.20. Zydus Cadila
6. Research Methodology & Scope
6.1. Research Scope & Deliverables
6.1.1. Objectives of Study
6.1.2. Scope of Study
6.2. Sources of Data
6.2.1. Primary Data Sources
6.2.2. Secondary Data Sources
6.3. Research Methodology
6.3.1. Evaluation of Proposed Market
6.3.2. Identification of Data Sources
6.3.3. Assessment of Market Determinants
6.3.4. Data Collection
6.3.5. Data Validation & Analysis
List of Tables
Table 1: Global Alzheimer's Disease Therapeutics and Diagnostics Market, Regional Outlook, 2021-2028 (In $ Million)
Table 2: Vendor Scorecard
Table 3: List of Contracts & Partnerships
Table 4: List of Business Expansions & Divestitures
Table 5: List of Acquisitions & Mergers
Table 6: List of New Product Launches
Table 7: Global Alzheimer's Disease Therapeutics and Diagnostics Market, by Therapeutics and Diagnostics, 2021-2028 (In $ Million)
Table 8: Global Therapeutics Market, by Drugs, 2021-2028 (In $ Million)
Table 9: Global Therapeutics Market, by Disease Stage, 2021-2028 (In $ Million)
Table 10: Global Therapeutics Market, by Generic and Branded, 2021-2028 (In $ Million)
Table 11: Global Diagnostics Market, by Type, 2021-2028 (In $ Million)
Table 12: Global Alzheimer's Disease Therapeutics and Diagnostics Market, Regional Outlook, 2021-2028 (In $ Million)
Table 13: North America Alzheimer's Disease Therapeutics and Diagnostics Market, Country Outlook, 2021-2028 (In $ Million)
Table 14: North America Alzheimer's Disease Therapeutics and Diagnostics Market, by Therapeutics and Diagnostics, 2021-2028 (In $ Million)
Table 15: North America Therapeutics Market, by Drugs, 2021-2028 (In $ Million)
Table 16: North America Therapeutics Market, by Disease Stage, 2021-2028 (In $ Million)
Table 17: North America Therapeutics Market, by Generic and Branded, 2021-2028 (In $ Million)
Table 18: North America Diagnostics Market, by Type, 2021-2028 (In $ Million)
Table 19: Europe Alzheimer's Disease Therapeutics and Diagnostics Market, Country Outlook, 2021-2028 (In $ Million)
Table 20: Europe Alzheimer's Disease Therapeutics and Diagnostics Market, by Therapeutics and Diagnostics, 2021-2028 (In $ Million)
Table 21: Europe Therapeutics Market, by Drugs, 2021-2028 (In $ Million)
Table 22: Europe Therapeutics Market, by Disease Stage, 2021-2028 (In $ Million)
Table 23: Europe Therapeutics Market, by Generic and Branded, 2021-2028 (In $ Million)
Table 24: Europe Diagnostics Market, by Type, 2021-2028 (In $ Million)
Table 25: Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market, Country Outlook, 2021-2028 (In $ Million)
Table 26: Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market, by Therapeutics and Diagnostics, 2021-2028 (In $ Million)
Table 27: Asia-Pacific Therapeutics Market, by Drugs, 2021-2028 (In $ Million)
Table 28: Asia-Pacific Therapeutics Market, by Disease Stage, 2021-2028 (In $ Million)
Table 29: Asia-Pacific Therapeutics Market, by Generic and Branded, 2021-2028 (In $ Million)
Table 30: Asia-Pacific Diagnostics Market, by Type, 2021-2028 (In $ Million)
Table 31: Latin America Alzheimer's Disease Therapeutics and Diagnostics Market, Country Outlook, 2021-2028 (In $ Million)
Table 32: Latin America Alzheimer's Disease Therapeutics and Diagnostics Market, by Therapeutics and Diagnostics, 2021-2028 (In $ Million)
Table 33: Latin America Therapeutics Market, by Drugs, 2021-2028 (In $ Million)
Table 34: Latin America Therapeutics Market, by Disease Stage, 2021-2028 (In $ Million)
Table 35: Latin America Therapeutics Market, by Generic and Branded, 2021-2028 (In $ Million)
Table 36: Latin America Diagnostics Market, by Type, 2021-2028 (In $ Million)
Table 37: Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics Market, Country Outlook, 2021-2028 (In $ Million)
Table 38: Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics Market, by Therapeutics and Diagnostics, 2021-2028 (In $ Million)
Table 39: Middle East and Africa Therapeutics Market, by Drugs, 2021-2028 (In $ Million)
Table 40: Middle East and Africa Therapeutics Market, by Disease Stage, 2021-2028 (In $ Million)
Table 41: Middle East and Africa Therapeutics Market, by Generic and Branded, 2021-2028 (In $ Million)
Table 42: Middle East and Africa Diagnostics Market, by Type, 2021-2028 (In $ Million)
List of Figures
Figure 1: Global Alzheimer's Disease Therapeutics and Diagnostics Market, Regional Outlook, 2021-2028 (In $ Million)
Figure 2: Industry Components
Figure 3: Pipeline Drugs Related to Alzheimer's Disease
Figure 4: Global Alzheimer's Disease Therapeutics and Diagnostics Market, by Therapeutics, 2021-2028 (In $ Million)
Figure 5: Global Therapeutics Market, by Marketed Drugs, 2021-2028 (In $ Million)
Figure 6: Global Therapeutics Market, by Pipeline Drugs, 2021-2028 (In $ Million)
Figure 7: Global Therapeutics Market, by Late Stage: Severe Ad, 2021-2028 (In $ Million)
Figure 8: Global Therapeutics Market, by Early/Middle Stage: Mild to Moderate Ad, 2021-2028 (In $ Million)
Figure 9: Global Therapeutics Market, by Prodromal Stage, 2021-2028 (In $ Million)
Figure 10: Global Therapeutics Market, by Branded, 2021-2028 (In $ Million)
Figure 11: Global Therapeutics Market, by Generic, 2021-2028 (In $ Million)
Figure 12: Global Alzheimer's Disease Therapeutics and Diagnostics Market, by Diagnostics, 2021-2028 (In $ Million)
Figure 13: Global Diagnostics Market, by Lumbar Puncture Test, 2021-2028 (In $ Million)
Figure 14: Global Diagnostics Market, by Positron Emission Tomography, 2021-2028 (In $ Million)
Figure 15: Global Diagnostics Market, by Electroencephalography, 2021-2028 (In $ Million)
Figure 16: Global Diagnostics Market, by Magnetic Resonance Imaging, 2021-2028 (In $ Million)
Figure 17: Global Diagnostics Market, by Computed Tomography, 2021-2028 (In $ Million)
Figure 18: Global Diagnostics Market, by Blood Test, 2021-2028 (In $ Million)
Figure 19: Global Diagnostics Market, by Other Diagnostics, 2021-2028 (In $ Million)
Figure 20: the United States Alzheimer's Disease Therapeutics and Diagnostics 2021-2028 (In $ Million)
Figure 21: Canada Alzheimer's Disease Therapeutics and Diagnostics 2021-2028 (In $ Million)
Figure 22: United Kingdom Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 23: France Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 24: Germany Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 25: Italy Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 26: Russia Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 27: Spain Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 28: Rest of Europe Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 29: China Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 30: India Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 31: Japan Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 32: Australia & New Zealand Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 33: South Korea Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 34: Asean Countries Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 35: Rest of Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market 2021-2028 (In $ Million)
Figure 36: Brazil Alzheimer's Disease Therapeutics & Diagnostics Market 2021-2028 (In $ Million)
Figure 37: Mexico Alzheimer's Disease Therapeutics & Diagnostics Market 2021-2028 (In $ Million)
Figure 38: Rest of Latin America Alzheimer's Disease Therapeutics & Diagnostics Market 2021-2028 (In $ Million)
Figure 39: Saudi Arabia Alzheimer's Disease Therapeutics & Diagnostics Market 2021-2028 (In $ Million)
Figure 40: United Arab Emirates Alzheimer's Disease Therapeutics & Diagnostics Market 2021-2028 (In $ Million)
Figure 41: Turkey Alzheimer's Disease Therapeutics & Diagnostics Market 2021-2028 (In $ Million)
Figure 42: South Africa Alzheimer's Disease Therapeutics & Diagnostics Market 2021-2028 (In $ Million)
Figure 43: Rest of Middle East & Africa Alzheimer's Disease Therapeutics & Diagnostics Market 2021-2028 (In $ Million)
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Allergan plc Acquired by Abbvie
  • Amarantus Bioscience Holdings Inc
  • Baxter International Inc
  • Biogen Inc
  • Cognoptix Inc
  • Eisai Co Ltd
  • Eli Lilly & Company
  • F Hoffmann La Roche
  • GE Healthcare
  • Johnson & Johnson
  • Lupin Limited
  • Luye Pharma Group
  • Merck & Co Inc
  • Novartis AG
  • Peoplebio Co
  • Pfizer Inc
  • Siemens Healthineers AG
  • Sun Pharmaceuticals Industries Ltd
  • Teva Pharmaceutical Industries Limited
  • Zydus Cadila
Note: Product cover images may vary from those shown

Loading
LOADING...